DOCSLIB.ORG

1 PHAR 827: Th1/Th17 Mediated Diseases [Psoriasis] (Leo R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 PHAR 827: Th1/Th17 Mediated Diseases [Psoriasis] (Leo R PHAR 827: Th1/Th17 mediated diseases [Psoriasis] (Leo R. Fitzpatrick Ph.D.) Key Learning Objectives: 1) Understand the overall pathogenesis for the development of plaque psoriasis. 2) Recognize the roles of Th17 and Th1 cells in the development of psoriasis. 3) Learn about established and novel drug approaches for psoriasis. 4) Understand the role of IL-22 in the pathogenesis of psoriasis. Overview Psoriasis is an immune-regulated skin disease with various clinical subtypes and disease activities. This TBL class will focus on the immunological basis for Plaque Psoriasis (Psoriasis vulgaris). The exact initial trigger(s) for the onset of psoriasis remains unidentified. However, environmental factors such as trauma could play a role in disease initiation. At the onset of new lesions in previously unaffected skin, plaque-type psoriasis frequently demonstrates highly inflammatory papules sometimes with an inflammatory border (see the left panel below). The pathology of initial psoriasis differs from stable plaque-type psoriasis (see the right panel below). Early lesions demonstrate the involvement of innate immune cells, such as neutrophils and macrophages. This activation of the innate immune system is followed by the appearance of the T cell-dominated immunopathology for stable plaque-type psoriasis. Therefore, it is possible that both highly inflammatory neutrophil predominant lesions and stable T cell predominant plaques can exist in the same patient. [Christophers et al., Br. J. Dermatol., 2014]. The source of controversy in the pathogenesis of psoriasis involved the relative importance of Th1 or Th17 cells in the process. Clinical data with specific monoclonal antibodies directed against IFN-γ (Fontolizumab) and IL-17A (Secukinumab) suggests that Th17 cells (and related cytokines) are important in the pathogenesis of chronic plaque psoriasis. Th22 cells are also involved in the etiology of this disease. 1 Th1 Cells and Psoriasis Pertinent clinical data showed that mRNA expression of IFN-γ (the key Th1 cytokine) is increased in the skin of patients with psoriasis (Ps) compared to normal (NL) subjects [Lowes et al., Journal of Investigative Dermatology, 2008]. Interestingly, the levels of IFN-γ mRNA were significantly reduced after Cyclosporine treatment for 14 to 56 days. Based on such data, an interesting hypothesis was put forth to explain the pathogenesis of psoriasis [Christophers et al., 2014]. Their etiology theory is shown within this figure. During the initiation phase of psoriasis, innate inflammatory cells would predominate, together with the presence of IL-1 produced by keratinocytes. Particularly, there would be the recruitment of neutrophils (PMN’s) into the epidermis. This first phase of psoriasis pathogenesis would be followed by the appearance of CD4+ cells (IL-17 and IL-22-producing Th17 cells). Next, IFN-γ- producing Th1 cells would become increasingly important in the developing plaque-type psoriasis. Thus, clinical development of single psoriasis lesions could follow periodic waves, where auto-inflammatory bursts of neutrophils and Th17 cells initiate the disease pathogenesis, 2 which would then turn into a Th1-associated inflammation. Th1 cells would then predominate in chronic psoriasis plaques [Christophers et al., 2014]. As a whole, this type of etiology would suggest that patients with plaque psoriasis should respond to treatment with an antibody directed against IFN-γ. However, recently published clinical data does not support this hypothesis. Specifically, 20 patients with moderate-severe stable plaque psoriasis were treated with Fontolizumab (HuZAF) at doses up to 10 mg/kg (by iv infusion) [Harden et al., J Allergy Clin Immunol, 2015]. Some of this clinical data is shown here. These data suggest that fontolizumab (HuZAF) treatment did not consistently reduce disease activity (PASI scores), or provide long-lasting efficacy in most patients with plaque psoriasis. The investigators concluded that anti-IFN-γ therapy had minimal efficacy in the treatment of psoriasis. They suggested that IFN-γ is not a major pathogenic cytokine in chronic psoriasis lesions, and also proposed changing the pathogenic model of the disease [Harden et al., 2015]. Th17 Cells and Psoriasis: Both the innate and adaptive immune systems are involved in psoriasis. Psoriatic plaque shows infiltration of activated T-cells, including Th17 and Th22 cells [Lonnberg et al. Clinical, Cosmetic and Investigational Dermatology, 2014 and Ports et al., British Journal of Dermatology, 2013]. The proposed central role of Th17 cells in the pathogenesis of psoriasis is shown within the figure on page 4 [S Handa, Indian Journal of Dermatology, Venereology and Leprology, 2013]. 3 IL-22 induces keratinocyte proliferation and epidermal acanthosis (skin thickening). IL-17 amplifies the inflammatory response by inducing production of pro-inflammatory cytokines (IL-6, IL-1β) and chemokines (e.g., IL-8, CCL-20). The important role of IL-17 in the pathogenesis of psoriasis suggested that antibody approaches directed against this cytokine (or its receptor) would be effective in patients with psoriasis. Some of the results obtained with Ixekizumab (an anti-IL-17A antibody) are shown on page 5. Specifically, this antibody improved moderate to severe psoriasis in this clinical trial, as determined by reductions in the Psoriasis Area and PASI scores. Also, the Static Physician’s Global Assessment (sPGA) was improved in the Ixekizumab treatment groups [Leonardi et al., NEJM, 2012]. 4 Of note, in January of 2015, the Food and Drug Administration (FDA) announced that it had approved Secukinumab (Cosentyx®) to treat adults with moderate-to-severe plaque psoriasis. Ixekizumab and Brodalumab were also approved for this indication in 2016. The recent clinical results with these antibodies clearly confirm an important role for IL-17 in the pathogenesis of psoriasis. In this regard, a recent review paper referred to psoriasis as a prototypic Th17 disease [Eberle et al., F1000 Research, 2016]. 5 Th17 Pathway Related Drugs: Summary A summary of drugs that can modulate the Th17 pathway (see the figure on page 4) and are being investigated/used for the treatment of psoriasis is shown in this table [Eberle et al., F100 Research, 2016]. Phase 3 Trials Other Drugs for Psoriasis Some clinicians use methotrexate as a systemic therapy for patients with psoriasis. Other clinicians use cyclosporine, which induces general immunosuppression, by preventing T cell activation and cytokine expression. Both compounds are effective in psoriasis. However, their long term use is complicated by drug related toxicities. Dimethyl fumarate (DMF) and Apremilast (a PDE4 inhibitor) modulate cytokine expression in activated dendritic cells. Biologics (like Infliximab) were developed to neutralize TNF-α, a critical mediator released by inflammatory Th1 and Th17 cells, but also by other cells (e.g., macrophages). Anti-TNF antibodies have greatly aided the therapy of psoriasis, with good response rates in some patients. Tofacitinib (Xeljanz®) is a novel, small-molecule Janus kinase (JAK) inhibitor currently in development for the treatment of several inflammatory diseases including psoriasis. It is also approved in the United States for the treatment of Rheumatoid Arthritis. The proposed mechanism of action for Tofacitinib is shown on page 7 [Tanaka and Yamaoka, Mod Rheumatol, 2013]. 6 Therefore, as shown in the relevant figure, Tofacitinib could inhibit the actions of both IL-17 and IFN-γ, by blocking the production of these cytokines. In patients with moderate-to-severe chronic plaque psoriasis, twelve-week treatment with oral tofacitinib (b.i.d.) improved clinical outcomes, as well as a patient assessment of disease severity and symptoms. Interestingly, there was an early onset of drug action noted in these patients [Mamolo et al., J Eur Acad Dermatol Venereol, 2013]. In October of 2015, the FDA rejected approval of Tofacitinib for psoriasis, and requested additional safety information. While Pfizer works with the FDA to provide the needed information related to possible future approval of the drug, another approach may be the topical use of Tofacitininib in psoriasis patients. 7 A published study found that topical application of Tofacitinib (in a specific ointment formulation) demonstrated efficacy in patients with mild to moderate plaque psoriasis. As shown here, topical application of Tofacitinib reduced the plaque area, as well as a calculated severity score in patients with psoriasis [Ports et al., 2013]. Severity Score = 8 Severity Score = 3 IL-22 and Psoriasis IL-22 is a cytokine that is involved in the modulation of tissue responses during inflammation. It is produced by CD4+ T lymphocyte subsets, while the expression of its receptor is restricted to cells of non-hematopoietic origin, particularly epithelial cells. In the skin, IL-22 induces keratinocyte proliferation and epidermal hyperplasia, inhibits terminal differentiation of keratinocytes, and promotes the production of antimicrobial proteins. IL-22 was initially thought to be produced mainly by Th17 cells. However, IL-22 production can also occur in an apparently unique subset of cells (i.e., Th22 cells), which lack the ability to produce IL-17 and interferon-γ. Importantly, Th22 cells are also enriched in the lesions of psoriasis patients. An important study has reported that epidermal Th22 cells in resolved psoriatic plaques were still functional after several years of disease remission underlining a role for this T cell
Load more

Recommended publications
  • 2017 American College of Rheumatology/American Association
    Arthritis Care & Research Vol. 69, No. 8, August 2017, pp 1111–1124 DOI 10.1002/acr.23274 VC 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology/ American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty SUSAN M. GOODMAN,1 BRYAN SPRINGER,2 GORDON GUYATT,3 MATTHEW P. ABDEL,4 VINOD DASA,5 MICHAEL GEORGE,6 ORA GEWURZ-SINGER,7 JON T. GILES,8 BEVERLY JOHNSON,9 STEVE LEE,10 LISA A. MANDL,1 MICHAEL A. MONT,11 PETER SCULCO,1 SCOTT SPORER,12 LOUIS STRYKER,13 MARAT TURGUNBAEV,14 BARRY BRAUSE,1 ANTONIA F. CHEN,15 JEREMY GILILLAND,16 MARK GOODMAN,17 ARLENE HURLEY-ROSENBLATT,18 KYRIAKOS KIROU,1 ELENA LOSINA,19 RONALD MacKENZIE,1 KALEB MICHAUD,20 TED MIKULS,21 LINDA RUSSELL,1 22 14 23 17 ALEXANDER SAH, AMY S. MILLER, JASVINDER A. SINGH, AND ADOLPH YATES Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be volun- tary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote benefi- cial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medi- cal knowledge, technology, and practice.
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH PrXELJANZ® tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate) PrXELJANZ® XR tofacitinib extended-release, tablets, oral 11 mg tofacitinib (as tofacitinib citrate) ATC Code: L04AA29 Selective Immunosuppressant Pfizer Canada ULC Date of Preparation: 17,300 Trans-Canada Highway October 24, 2019 Kirkland, Quebec H9J 2M5 TMPF PRISM C.V. c/o Pfizer Manufacturing Holdings LLC Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2019 Submission Control No: 230976 XELJANZ/XELJANZ XR Page 1 of 80 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 ADVERSE REACTIONS..................................................................................................15 DRUG INTERACTIONS ..................................................................................................29 DOSAGE AND ADMINISTRATION..............................................................................34 OVERDOSAGE ................................................................................................................38 ACTION AND CLINICAL PHARMACOLOGY ............................................................38
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Dissecting Intratumor Heterogeneity of Nodal B Cell Lymphomas on the Transcriptional, Genetic, and Drug Response Level
    bioRxiv preprint doi: https://doi.org/10.1101/850438; this version posted December 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Dissecting intratumor heterogeneity of nodal B cell lymphomas on the 2 transcriptional, genetic, and drug response level 3 4 Tobias Roider1-3, Julian Seufert4-5, Alexey Uvarovskii6, Felix Frauhammer6, Marie Bordas4,7, 5 Nima Abedpour8, Marta Stolarczyk1, Jan-Philipp Mallm9, Sophie Rabe1-3,5,10, Peter-Martin 6 Bruch1-3, Hyatt Balke-Want11, Michael Hundemer1, Karsten Rippe9, Benjamin Goeppert12, 7 Martina Seiffert7, Benedikt Brors13, Gunhild Mechtersheimer12, Thorsten Zenz14, Martin 8 Peifer8, Björn Chapuy15, Matthias Schlesner4, Carsten Müller-Tidow1-3, Stefan Fröhling10,16, 9 Wolfgang Huber2,3, Simon Anders6*, Sascha Dietrich1-3,10* 10 11 1 Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, 12 Germany, 13 2 Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany, 14 3 European Molecular Biology Laboratory (EMBL), Heidelberg, Germany, 15 4 Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany, 16 5 Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany, 17 6 Center for Molecular Biology of the University of Heidelberg (ZMBH), Heidelberg, Germany, 18 7 Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany, 19 8 Department for Translational
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • XELJANZ (Tofacitinib)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Psoriatic Arthritis (in combination with nonbiologic DMARDs) These highlights do not include all the information needed to use XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. (2.2) XELJANZ/XELJANZ XR safely and effectively. See full prescribing Recommended dosage in patients with moderate and severe renal information for XELJANZ. impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. (2, 8.7, 8.8) ® XELJANZ (tofacitinib) tablets, for oral use Ulcerative Colitis ® XELJANZ XR (tofacitinib) extended-release tablets, for oral use XELJANZ 10 mg twice daily for at least 8 weeks; then 5 or 10 mg Initial U.S. Approval: 2012 twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to WARNING: SERIOUS INFECTIONS AND MALIGNANCY maintain response. (2.3) See full prescribing information for complete boxed warning. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage Serious infections leading to hospitalization or death, including recommended for patients with normal renal and hepatic function. (2, 8.7, tuberculosis and bacterial, invasive fungal, viral, and other 8.8) opportunistic infections, have occurred in patients receiving Dosage Adjustment XELJANZ. (5.1) See the full prescribing information for dosage adjustments by indication If a serious infection develops, interrupt XELJANZ/XELJANZ XR for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patients until the infection is controlled. (5.1) with moderate or severe renal impairment or moderate hepatic Prior to starting XELJANZ/XELJANZ XR, perform a test for latent impairment; and patients with lymphopenia, neutropenia, or anemia.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]
  • Initial Safety Trial Results Find Increased Risk of Serious Heart-Related
    Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) FDA will evaluate the trial results FDA previously communicated about the safety clinical trial with Xeljanz, Xeljanz XR (tofacitinib) in February 2019 and July 2019. 2-4-2021 FDA Drug Safety Communication The U.S. Food and Drug Administration (FDA) is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final results are not yet available. We will evaluate the clinical trial results we have received to date and will work with the drug manufacturer to obtain further information as soon as possible. We will communicate our final conclusions and recommendations when we have completed our review or have more information to share. Patients should not stop taking tofacitinib without first consulting with your health care professionals, as doing so may worsen your condition. Talk to your health care professionals if you have any questions or concerns. Health care professionals should consider the benefits and risks of tofacitinib when deciding whether to prescribe or continue patients on the medicine. Continue to follow the recommendations in the tofacitinib prescribing information. Tofacitinib was first approved in 2012 to treat adults with rheumatoid arthritis (RA) who did not respond well to the medicine methotrexate.
    [Show full text]
  • Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study Author Nash, Peter, Coates, Laura C, Kivitz, Alan, Mease, Philip J, Gladman, Dafna D, Covarrubias- Cobos, Jose A, Fitzgerald, Oliver, Fleishaker, Dona, Wang, Cunshan, Wu, Joseph, Hsu, Ming- Ann, Menon, Sujatha, Fallon, Lara, Romero, Ana Belen, Kanik, Keith S Published 2020 Journal Title Rheumatology and Therapy Version Version of Record (VoR) DOI https://doi.org/10.1007/s40744-020-00209-4 Copyright Statement © The Author(s) 2020. This article is licensed under a Creative Commons Attribution- NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you Rheumatol Ther will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/. Downloaded from http://hdl.handle.net/10072/394642 Griffith Research Online https://research-repository.griffith.edu.au Rheumatol Ther https://doi.org/10.1007/s40744-020-00209-4 ORIGINAL RESEARCH Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study Peter Nash .
    [Show full text]
  • Clinical Policy: Tofacitinib (Xeljanz/Xeljanz
    Clinical Policy: Tofacitinib (Xeljanz/Xeljanz XR) Reference Number: PA.CP.PHAR.267 Effective Date: 01/18 Last Review Date: 07/17 Revision Log Line of Business: Medicaid Description Tofacitinib (Xeljanz®/Xeljanz® XR) is a Janus kinase (JAK) inhibitor. FDA approved indication Xeljanz and Xeljanz XR are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). They may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Limitation of use: Use of Xeljanz or Xeljanz XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria) It is the policy of Pennsylvania Health and Wellness® that Xeljanz and Xeljanz XR are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Rheumatoid Arthritis (must meet all): 1. Diagnosis of RA per American College of Rheumatology (ACR) criteria (refer to Appendix B); 2. Prescribed by or in consultation with a rheumatologist; 3. Age ≥ 18 years; 4. Member meets one of the following (a or b): a. Failure of MTX for ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects are experienced; b. If intolerance or contraindication to MTX, failure of sulfasalazine, leflunomide, or hydroxychloroquine for ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects are experienced; 5. Failure of etanercept (Enbrel is preferred) AND adalimumab (Humira is preferred), each trialed for ≥ 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced; *Prior authorization is required for etanercept and adalimumab 6.
    [Show full text]
  • Tofacitinib (Xeljanz) Drug Monograph
    PBM-MAP-VPE Drug Monograph: Tofacitinib Tofacitinib (Xeljanz®) National Drug Monograph April 2014 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. These documents will be updated when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. Executive Summary: Tofacitinib is a new oral therapy for the treatment of rheumatoid arthritis that provides a novel mechanistic approach via JAK intracellular pathways. Tofacitinib is a Janus kinase (JAK) inhibitor. The efficacy of tofacitinib was evaluated under the oral rheumatoid arthritis trials program (ORAL). Efficacy: Tofacitinib is FDA-approved for the treatment of adult patients with moderate to severe, active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs (e.g. hydroxychloroquine, leflunomide, minocycline, sulfasalazine). Tofacitinib is dosed as 5 mg orally, twice daily, with or without food. Among the phase 3 trials, a statistically higher percentage of patients receiving tofacitinib achieved the primary endpoint of ACR20 at the pre-defined time point (month 3 vs. 6) compared to placebo. In five of the phase 3 trials, where tofacitinib was initiated after inadequate response to either biologic or non-biologic DMARD, tofacitinib, in combination with non-biologic DMARD therapy, was more effective than placebo. Adding the comparator, adalimumab 40mg every other week, showed that all three treatment arms (tofacitinib 5mg, 10mg and adalimumab) achieved a greater ACR20 response at month 6 compared to placebo, with tofacitinib and adalimumab responses being numerically similar.
    [Show full text]